You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Potent and selective CB1 receptor antagonist (IC50 values are 25 and 10 nM for human and rat CB1R, respectively). Exhibits >400-fold selectivity for CB1 over CB2 receptors. Attenuates Olanzapine (Cat. No. 4349) induced weight gain and food intake in rats with no effect on energy expenditure or motility. Also improves cognitive function in rodent schizophrenia models and ameliorates extrapyramidal side-effects of antipsychotics.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 497.38. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.01 mL||10.05 mL||20.11 mL|
|5 mM||0.4 mL||2.01 mL||4.02 mL|
|10 mM||0.2 mL||1.01 mL||2.01 mL|
|50 mM||0.04 mL||0.2 mL||0.4 mL|
References are publications that support the biological activity of the product.
Herling et al (2007) CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats. Am.J.Physiol.Endocrinol.Metab. 293 E826 PMID: 17595216
Liebig et al (2010) Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625. Obesity 18 1952 PMID: 20168311
Black et al (2011) AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. Psychopharmacology (Berl.) 215 149 PMID: 21181124
If you know of a relevant reference for AVE 1625, please let us know.
View Related Products by Product Action
Keywords: AVE 1625, AVE 1625 supplier, AVE1625, cannabinoid, receptor, antagonist, potent, selective, CB1, CB1R, anti-obesity, Drinabant, Receptors, 6763, Tocris Bioscience
Citations for AVE 1625
Citations are publications that use Tocris products.
Currently there are no citations for AVE 1625. Do you know of a great paper that uses AVE 1625 from Tocris? Please let us know.
Reviews for AVE 1625
There are currently no reviews for this product. Be the first to review AVE 1625 and earn rewards!
Have you used AVE 1625?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.